Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:amprenavir
|
| gptkbp:associatedWith |
fosamprenavir
|
| gptkbp:ATCCode |
J05AE05
|
| gptkbp:CASNumber |
161814-49-9
|
| gptkbp:chemicalFormula |
C25H35N3O6S
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:drugClass |
protease inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
Agenerase
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:market |
discontinued
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:regulates |
approved (1999)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting rash oral paresthesia |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Amprenavir
|
| gptkbp:bfsLayer |
7
|